RT Journal Article
SR Electronic
T1 A scalable saliva-based, extraction-free rt-lamp protocol for sars-cov-2 diagnosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.27.20220541
DO 10.1101/2020.10.27.20220541
A1 Asprino, Paula
A1 Bettoni, Fabiana
A1 Camargo, Anamaria
A1 Coelho, Diego
A1 Coppini, Guilherme
A1 Correa, Igor
A1 Freitas, Erika
A1 Inoue, Lilian
A1 Kitajima, João Paulo
A1 Kuroki, Mayra
A1 Masotti, Cibele
A1 Marques, Tatiana
A1 Reis, Alice
A1 Reis, Luiz Fernando
A1 Santos, Bibiana
A1 Santos, Ernande dos
A1 Schlesinger, David
A1 Sena, Cecília
A1 Spadaccini, Talita
A1 Taniguti, Lucas
YR 2020
UL http://medrxiv.org/content/early/2020/10/27/2020.10.27.20220541.abstract
AB Scalable, cost-effective screening methods are an essential tool to control SARS-CoV-2 spread. We have developed a straight saliva-based, RNA extraction-free, RT-LAMP test that is comparable to current nasopharyngeal swab RT-PCR tests in both sensitivity and specificity. Using a 2-step readout of fluorescence and melting-point curve analysis, the test is scalable to more than 30,000 tests per day with average turnaround time of less than 3 hours. The test was validated using samples from 244 symptomatic patients, and showed sensitivity of 78.9% (vs. 85.5% for nasopharyngeal swabs RT-PCR) and specificity of 100% (vs. 100% for nasopharyngeal swabs RT-PCR). Our method is therefore accurate, robust, time and cost effective and therefore can be used for screening of SARS-CoV-2.Competing Interest StatementResearch and development of this protocol was financed by Mendelics Analise Genomica.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval # HSL 2020-43 (Hospital Sirio-Libanes, Sao Paulo, Brazil)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request.